Back

B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy and cardiovascular outcomes Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Takanori Nagahiro

Yokohama City University Hospital, Yokohama (Japan)

5 More presentations in this session

Presentation thumbnail
Cardiovascular and renal outcomes of Semaglutide in patients with Type 2 Diabetes Mellitus with established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: A Meta-Analysis
Doctor F. Lumancas (Cebu City, PH)
Abstract
Presentation thumbnail
Impact of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a meta-analysis of randomized controlled trials
Doctor C. Cotticelli (Naples, IT)
Abstract
Presentation thumbnail
Effects of luseogliflozin on sympathetic nerve activity:a dual assessment using iodine-123-metaiodobenzylguanidine and muscle sympathetic nerve activity
Mr T. Hirai (Kanazawa, JP)
Abstract
Presentation thumbnail
Comparative cardiovascular efficacy of individual GLP-1 receptor agonists and tirzepatide: a Bayesian network meta-analysis of 13 cardiovascular outcome trials
Ms Y. Srivastava (IN)
Abstract
Presentation thumbnail
Regression of microalbuminuria predicts cardiovascular risk reduction with GLP-1 receptor agonist therapy
Doctor I. Figueroa Baez (San Juan, PR)
Abstract

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
28 August 2020
thumbnail
Webinar
Natriuretic peptides: role for risk prediction and treatment efficacy
7 October 2021
thumbnail
Congress Session
Hypertension with cardiometabolic comorbidities: which drugs to select and which to avoid
30 August 2025
thumbnail
Congress Presentation
Changes in NT-proBNP following patiromer-facilitated optimisation of RAASi in patients with HFrEF with current or recent hyperkalaemia: a post hoc analysis of the DIAMOND study
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources